Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline (GSK) responds to Senate Finance Committee letter of 12 July to FDA
The Senate Finance Committee (SFC) has released a small subset of the 14 million pages of documents provided to plaintiffs&apos.
-
Data support Avandia (rosiglitazone maleate) cardiovascular safety profile
The U.S. Food and Drug Administration (FDA) today posted a comprehensive review conducted by GlaxoSmithKline (GSK).
-
GSK EU regulatory update on Avandia (rosiglitazone)
GSK today confirmed that on behalf of EMA, the CHMP is to review the benefit/risk profile of Avandia (rosiglitazone).
-
GSK and EDB commit $35 million (USD) in funding to support research in green and sustainable manufacturing in Singapore
GSK and the Singapore EDB, the government agency responsible for economic growth and development.
-
GlaxoSmithKline and Genmab announce amendment to Ofatumumab agreement
GSK and GEN announced today an amendment to the ofatumumab co-development and commercialisation agreement.
-
GlaxoSmithKline creates a new operating unit dedicated to expanding access to medicines for people living in the world’s poorest countries
As part of its commitment to further transform the companys approach to diseases that disproportionately affect the world's poorest people.
-
GSK and Aptuit finalise agreement for Aptuit to acquire GSK’s research operations in Italy
Augments Aptuit's global, integrated scientific and operational capabilities and preserves scientific expertise at the centre
-
GlaxoSmithKline receives EU authorisation for a new therapeutic indication for Tyverb® (lapatinib)
GSK confirmed that EC has granted a variation to the conditional marketing authorisation for Tyverb in the EU for therapeutic indication.
-
GlaxoSmithKline enters agreement with Medivir for exclusive rights to cold sore treatment Xerclear™
GlaxoSmithKline (GSK) and Medivir (STO: MVIR-B) today announced an exclusive agreement for the commercialisation of cold sore treatment.
-
GlaxoSmithKline receives conditional marketing authorisation in the EU for Votrient® (pazopanib)
As part of these conditions, GSK will provide data from ongoing clinical studies.
-
FDA approves Jalyn™, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate
BPH is one of the most common prostate disorders, affecting nearly half of all men 50 years of age or older in the U.S.
-
GlaxoSmithKline Receives Complete Response from FDA for Candidate Meningococcal and Hib Combination Vaccine
Meningococcal and Hib diseases are caused by potentially deadly bacteria that can lead to meningitis and other very serious complications.
-
GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix
GSK today announced that it has acquired Laboratorios Phoenix, a leading pharmaceutical business, a cash consideration of $253 million.
-
Regulatory update – BLA filed for Benlysta® (belimumab)
GSK announced today that Human Genome Sciences, Inc. (HGS) has submitted a Biologics License Application (BLA) to the U.S.
-
Regulatory update - Benlysta® (belimumab)
GSK announced today that it has submitted a MAA to the EMA, for Benlysta (belimumab) for reducing disease activity in adult patients.
-
GSK announces revised product labels for Serevent and Advair
The changes communicated by the FDA reflect class labeling for all LABA containing products and are specific to product labels in the U.S.
-
European Medicines Agency maintains position on the continued use of Rotarix™ (rotavirus vaccine)
GSK today confirmed that following a meeting of the Committee for Medicinal Products for Human Use (CHMP).
-
Viani (Seretide): German patent litigation update
GSK today confirmed that the Federal Patents Court in Munich, Germany, has ruled in patent litigation regarding GSKs product Viani.
-
New research identifies promising leads to follow in search for medicines to fight malaria
New research conducted by GSK was published in Nature1 identifying promising potential leads to develop new medicines to treat malaria.
-
FDA says Healthcare Providers can resume use of Rotarix (Rotavirus Vaccine, Live, Oral)
GSK announced that the Food and Drug Administration (FDA) has determined that U.S. healthcare practitioners can resume the use of Rotarix.